Medical CannabisECIPCannaNCT06597097
Evaluation of Interprofessional Relations Between Primary Care and Hospital Centers in the Experimentation of Medical Cannabis in France Carried Out by the ANSM (ECIPCanna)
An observational study of Medical Cannabis, run by University Hospital, Brest at 1 site in France.
Trial summary
An observational study to explore inter-professional relations and perceptions around the experimentation of medical cannabis, conducted by the French National Agency for Safety and Health. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Medical Cannabis
- How many people
- 108 participants
- Where
- 1 siteFrance
- Study dates
- 1 Oct 2024to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Healthcare professionals participating in the experiment conducted by the French National Agency for Safety and Health: * Hospital doctors * General practitioners * Community pharmacists * Hospital pharmacists
Who may be able to join
- Healthcare professional participating in the experiment conducted by the the French National Agency for Safety and Health: Hospital doctor, general practitioner, community pharmacist, or hospital pharmacist
- Non-opposition
Who cannot join
- Refusal of participation by hospital doctor, general practitioner, community pharmacist, or hospital pharmacist
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of Interprofessional Relations Between Primary Care and Hospital Centers in the Experimentation of Medical Cannabis in France Carried Out by the ANSM
An observational study to explore inter-professional relations and perceptions around the experimentation of medical cannabis, conducted by the French National Agency for Safety and Health. The study aims to identify the barriers and facilitators to prescribing and dispensing medical cannabis and to analyse healthcare professionals' perceptions of medical cannabis in France. Using a qualitative method based on semi-directed interviews and focus groups, the study will involve hospital physicians, general practitioners, and community and hospital pharmacists participating in the the French National Agency for Safety and Health experiment. The primary objective is to understand the dynamics between health professionals involved in the medical cannabis programme, while secondary objectives include proposing strategies to overcome barriers to the provision of medical cannabis.
- Conditions
- Medical Cannabis
- Keywords
- Cannabis for medical use, Outpatient medicine, Prescription, Pharmacy, Primary care
What is being measured
The primary outcome is the main question the study is designed to answer.
Exploring the inter-professional relationships of those involved in the medical cannabis experiment being conducted by the French National Agency for Safety and Health
Construct mental maps of representations relating to the prescription and dispensing of medical cannabis.
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start1 Oct 2024 (estimated)
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medical CannabisStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06597097
- Sponsor's protocol ID
- 29BRC23.0215
- Acronym
- ECIPCanna
- Status last verified
- Sep 2024
- First submitted
- 4 Apr 2024
- Last updated
- 19 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Interprofessional Relations Between Primary Care and Hospital Centers in the Experimentation of Medical Cannabis in France Carried Out by the ANSM
- ClinicalTrials.gov ID
- NCT06597097
- Acronym / sponsor ID
- ECIPCanna / 29BRC23.0215
- Conditions
- Medical Cannabis
- Keywords
- Cannabis for medical use, Outpatient medicine, Prescription, Pharmacy, Primary care
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 1 Oct 2024 (estimated)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An observational study to explore inter-professional relations and perceptions around the experimentation of medical cannabis, conducted by the French National Agency for Safety and Health. The study aims to identify the barriers and facilitators to prescribing and dispensing medical cannabis and to analyse healthcare professionals' perceptions of medical cannabis in France. Using a qualitative method based on semi-directed interviews and focus groups, the study will involve hospital physicians, general practitioners, and community and hospital pharmacists participating in the the French National Agency for Safety and Health experiment. The primary objective is to understand the dynamics between health professionals involved in the medical cannabis programme, while secondary objectives include proposing strategies to overcome barriers to the provision of medical cannabis.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Healthcare professionals participating in the experiment conducted by the French National Agency for Safety and Health: * Hospital doctors * General practitioners * Community pharmacists * Hospital pharmacists
Key inclusion criteria (2 listed)
- Healthcare professional participating in the experiment conducted by the the French National Agency for Safety and Health: Hospital doctor, general practitioner, community pharmacist, or hospital pharmacist
- Non-opposition
Key exclusion criteria (1 listed)
- Refusal of participation by hospital doctor, general practitioner, community pharmacist, or hospital pharmacist
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Exploring the inter-professional relationships of those involved in the medical cannabis experiment being conducted by the French National Agency for Safety and Health
Time frame: 1 day
Construct mental maps of representations relating to the prescription and dispensing of medical cannabis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2024.
- Individual participant dataSharing planned: Yes. All collected data that underlie results in a publication
Related trials for Medical Cannabis
Active, not recruitingPhase 1/2
Pilot Study of MC in Paediatric Palliative Care
Palliative Care
RecruitingPhase 2
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Active, not recruitingPhase 2
PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product
Chronic Pain
Not yet recruitingPhase 2
Full-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in Women
Chronic Pain, Fibromyalgia
RecruitingObservational study
Medical Marijuana and Open Road Driving Task
Medical Cannabis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Medical Cannabis, run by University Hospital, Brest at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exploring the inter-professional relationships of those involved in the medical cannabis experiment being conducted by the French National Agency for Safety and Health (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.